Design of Dual COX-2 and 5-LOX Inhibitors with Iron-Chelating Properties Using Structure-Based and Ligand-Based Methods

被引:0
|
作者
Boskovic, Jelena [1 ]
Ruzic, Dusan [1 ]
Cudina, Olivera [1 ]
Nikolic, Katarina [1 ]
Dobricic, Vladimir [1 ]
机构
[1] Univ Belgrade, Fac Pharm, Dept Pharmaceut Chem, Belgrade, Serbia
关键词
Drug design; 3D-QSAR; molecular docking; iron chelation; dual COX-2 and 5-LOX inhibitors; ADMET prediction; BIOLOGICAL EVALUATION; SEMIEMPIRICAL METHODS; VALIDATION; 5-LIPOXYGENASE; ANALOGS; CYCLOOXYGENASE-2; OPTIMIZATION; PARAMETERS; PHENOTYPE; ALGORITHM;
D O I
10.2174/1570180818666210714161908
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Inflammation is a critical component of many disease progressions, such as malignancy, cardiovascular and rheumatic diseases. The inhibition of inflammatory mediators synthesis by modulation of cyclooxygenase (COX) and lipoxygenase (LOX) pathways provides challenging strategy for development of more effective drugs. Objective: The aim of this study was to design dual COX-2 and 5-LOX inhibitors with iron-chelating properties using a combination of ligand-based (three-dimensional quantitative structure-activity relationship (3D-QSAR)) and structure-based (molecular docking) methods. Methods: The 3D-QSAR analysis was applied on a literature dataset consisting of 28 dual COX-2 and 5-LOX inhibitors in Pentacle software. The quality of developed COX-2 and 5-LOX 3D-QSAR models were evaluated by internal and external validation methods. The molecular docking analysis was performed in GOLD software, while selected ADMET properties were predicted in ADMET predictor software. Results: According to the molecular docking studies, the class of sulfohydroxamic acid analogues, previously designed by 3D-QSAR, were clustered as potential dual COX-2 and 5-LOX inhibitors with iron-chelating properties. Based on the 3D-QSAR and molecular docking, 1j, 1g and 1l were selected as the most promising dual COX-2 and 5-LOX inhibitors. According to the in silico ADMET predictions, all compounds had ADMET_Risk score less than 7 and CYP_Risk score lower than 2.5. Designed compounds were not estimated as hERG inhibitors and 1j had improved intrinsic solubility (8.704) in comparison to the dataset compounds (0.411-7.946). Conclusion: By combining 3D-QSAR and molecular docking, three compounds (1j, 1g and 1l) were selected as the most promising designed dual COX-2 and 5-LOX inhibitors, for which good activity, as well as favourable ADMET properties and toxicity, are expected.
引用
收藏
页码:279 / 292
页数:14
相关论文
共 50 条
  • [31] Discovery of new thymol-3,4-disubstituted thiazole hybrids as dual COX-2/5-LOX inhibitors with in vivo proof
    El-Miligy, Mostafa M. M.
    Al-Kubeisi, Ahmed K.
    Nassra, Rasha A.
    El-Zemity, Saad R.
    Hazzaa, Aly A.
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2024, 39 (01)
  • [32] Structure-based and ligand-based drug design for microsomal prostaglandin E synthase-1 inhibitors
    Li, Chia-Ling
    Chang, Tung-Ti
    Sun, Mao-Feng
    Chen, Hsin-Yi
    Tsai, Fuu-Jen
    Fisher, Mark
    Chen, Calvin Yu-Chian
    Lee, Chun-Lin
    Fang, Wen-Chang
    Wong, Yung-Hao
    MOLECULAR SIMULATION, 2011, 37 (03) : 226 - 236
  • [33] Current Trends in Virtual High Throughput Screening Using Ligand-Based and Structure-Based Methods
    Sukumar, Nagamani
    Das, Sourav
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2011, 14 (10) : 872 - 888
  • [34] Identification of novel cathepsin K inhibitors using ligand-based virtual screening and structure-based docking
    Wang, Yali
    Li, Ruolan
    Zheng, Zhihui
    Yi, Hong
    Li, Zhuorong
    RSC ADVANCES, 2016, 6 (86): : 82961 - 82968
  • [35] Novel 5,6-diphenyl-1,2,4-triazine-3-thiol derivatives as dual COX-2/5-LOX inhibitors devoid of cardiotoxicity
    Saraf, Poorvi
    Tripathi, Prabhash Nath
    Tripathi, Manish Kumar
    Tripathi, Avanish
    Verma, Himanshu
    Waiker, Digambar Kumar
    Singh, Royana
    Shrivastava, Sushant Kumar
    BIOORGANIC CHEMISTRY, 2022, 129
  • [36] Ligand-Based and Structure-Based Virtual Screening of New Sodium Glucose Cotransporter Type 2 Inhibitors
    Estrada, Ana Karen
    Mendez-Alvarez, Domingo
    Juarez-Saldivar, Alfredo
    Lara-Ramirez, Edgar E.
    Martinez-Vazquez, Ana Veronica
    Villalobos-Rocha, Juan Carlos
    Palos, Isidro
    Ortiz-Perez, Eyra
    Rivera, Gildardo
    MEDICINAL CHEMISTRY, 2023, 19 (10) : 1049 - 1060
  • [37] Combined ligand-based and structure-based design of PDE 9A inhibitors against Alzheimer’s disease
    Rayala Swetha
    Anjali Sharma
    Ravi Singh
    Ankit Ganeshpurkar
    Devendra Kumar
    Ashok Kumar
    Sushil K. Singh
    Molecular Diversity, 2022, 26 : 2877 - 2892
  • [38] Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents
    Li, Zhang
    Wang, Zhong-Chang
    Li, Xin
    Abbas, Muhammad
    Wu, Song-Yu
    Ren, Shen-Zhen
    Liu, Qi-Xing
    Liu, Yi
    Chen, Peng-Wen
    Duan, Yong-Tao
    Lv, Peng-Cheng
    Zhu, Hai-Liang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 169 : 168 - 184
  • [39] Combined ligand-based and structure-based design of PDE 9A inhibitors against Alzheimer's disease
    Swetha, Rayala
    Sharma, Anjali
    Singh, Ravi
    Ganeshpurkar, Ankit
    Kumar, Devendra
    Kumar, Ashok
    Singh, Sushil K.
    MOLECULAR DIVERSITY, 2022, 26 (05) : 2877 - 2892
  • [40] Towards safer anti-inflammatory therapy: synthesis of new thymol-pyrazole hybrids as dual COX-2/5-LOX inhibitors
    El-Miligy, Mostafa M. M.
    Al-Kubeisi, Ahmed K.
    Bekhit, Mohamed G.
    El-Zemity, Saad R.
    Nassra, Rasha A.
    Hazzaa, Aly A.
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01) : 294 - 308